Treatment pattern for MCL in 2 different eras
| Treatment . | Patients age 65 years or younger(n = 184) . | Patients age older than 65 years(n = 159) . | ||||
|---|---|---|---|---|---|---|
| Era 1 (n = 93) . | Era 2 (n = 91) . | P . | Era 1 (n = 82) . | Era 2 (n = 77) . | P . | |
| Frontline treatment | <.001 | <.001 | ||||
| R-Hyper-CVAD/R-MA | 15 (16.1) | 8 (8.8) | 2 (2.4) | 0 (0.0) | ||
| R-maxi-CHOP/R-HiDAC (Nordic regimen) or R-CHOP/R-DHAP | 1 (1.1) | 24 (26.4) | 0 (0.0) | 2 (2.6) | ||
| R-CHOP or R-CHOP-like | 60 (64.5) | 32 (35.2) | 32 (39.0) | 11 (14.3) | ||
| R-bendamustine | 0 (0.0) | 11 (12.1) | 0 (0.0) | 38 (49.4) | ||
| Nonstandard systemic therapy | 8 (8.6) | 3 (3.3) | 30 (36.6) | 10 (13.0) | ||
| R-2-CdA | 5 | 1 | 21 | 5 | ||
| R-FCM | 1 | 1 | 3 | 1 | ||
| R only | 0 | 1 | 5 | 4 | ||
| Chemo without R | 2 | 0 | 1 | 0 | ||
| Nonsystemic treatment | 9 (9.7) | 13 (14.3) | 18 (22.0) | 16 (20.8) | ||
| Surgery | 3 | 2 | 0 | 1 | ||
| Radiation therapy | 0 | 0 | 3 | 2 | ||
| Observation only | 6 | 11 | 15 | 13 | ||
| ASCT consolidation | .87 | .84 | ||||
| Yes | 42 (45.2) | 40 (44.0) | 6 (7.3) | 5 (6.5) | ||
| Induction regimen before ASCT | ||||||
| R-Hyper-CVAD/R-MA | 2 | 6 | 0 | 0 | ||
| R-maxi-CHOP/R-HiDAC (Nordic regimen) or R-CHOP/R-DHAP | 1 | 15 | 0 | 1 | ||
| R-CHOP or R-CHOP-like | 39 | 15 | 6 | 2 | ||
| R-bendamustine | 0 | 4 | 0 | 2 | ||
| No | 51 (54.8) | 51 (56.0) | 76 (92.7) | 72 (93.5) | ||
| Rituximab maintenance | .97 | .38 | ||||
| Yes | 5 (5.4) | 5 (5.5) | 8 (9.8) | 11 (14.3) | ||
| No | 88 (94.6) | 86 (94.5) | 74 (90.2) | 66 (85.7) | ||
| Treatment . | Patients age 65 years or younger(n = 184) . | Patients age older than 65 years(n = 159) . | ||||
|---|---|---|---|---|---|---|
| Era 1 (n = 93) . | Era 2 (n = 91) . | P . | Era 1 (n = 82) . | Era 2 (n = 77) . | P . | |
| Frontline treatment | <.001 | <.001 | ||||
| R-Hyper-CVAD/R-MA | 15 (16.1) | 8 (8.8) | 2 (2.4) | 0 (0.0) | ||
| R-maxi-CHOP/R-HiDAC (Nordic regimen) or R-CHOP/R-DHAP | 1 (1.1) | 24 (26.4) | 0 (0.0) | 2 (2.6) | ||
| R-CHOP or R-CHOP-like | 60 (64.5) | 32 (35.2) | 32 (39.0) | 11 (14.3) | ||
| R-bendamustine | 0 (0.0) | 11 (12.1) | 0 (0.0) | 38 (49.4) | ||
| Nonstandard systemic therapy | 8 (8.6) | 3 (3.3) | 30 (36.6) | 10 (13.0) | ||
| R-2-CdA | 5 | 1 | 21 | 5 | ||
| R-FCM | 1 | 1 | 3 | 1 | ||
| R only | 0 | 1 | 5 | 4 | ||
| Chemo without R | 2 | 0 | 1 | 0 | ||
| Nonsystemic treatment | 9 (9.7) | 13 (14.3) | 18 (22.0) | 16 (20.8) | ||
| Surgery | 3 | 2 | 0 | 1 | ||
| Radiation therapy | 0 | 0 | 3 | 2 | ||
| Observation only | 6 | 11 | 15 | 13 | ||
| ASCT consolidation | .87 | .84 | ||||
| Yes | 42 (45.2) | 40 (44.0) | 6 (7.3) | 5 (6.5) | ||
| Induction regimen before ASCT | ||||||
| R-Hyper-CVAD/R-MA | 2 | 6 | 0 | 0 | ||
| R-maxi-CHOP/R-HiDAC (Nordic regimen) or R-CHOP/R-DHAP | 1 | 15 | 0 | 1 | ||
| R-CHOP or R-CHOP-like | 39 | 15 | 6 | 2 | ||
| R-bendamustine | 0 | 4 | 0 | 2 | ||
| No | 51 (54.8) | 51 (56.0) | 76 (92.7) | 72 (93.5) | ||
| Rituximab maintenance | .97 | .38 | ||||
| Yes | 5 (5.4) | 5 (5.5) | 8 (9.8) | 11 (14.3) | ||
| No | 88 (94.6) | 86 (94.5) | 74 (90.2) | 66 (85.7) | ||
All data are No. (%).
R-2-CdA, rituximab plus cladribine; R-FCM, rituximab plus fludarabine, cyclophosphamide, and mitoxantrone.